Seeking Alpha

Enanta Pharmaceuticals FQ3 beats on fewer losses

  • Enanta Pharmaceuticals (ENTA +6%) moves up after beating FQ3 estimates earlier this morning.
  • EPS losses came in at $0.23 per share, on revenues of $1.6M.
  • Analysts expected loss per share of $0.31.
  • In the same period last year, net loss was $3.5M, or $4.31 per share, on revenues of $2.5M.
  • Cash and equivalents totaled $114.8M at the end of June, compared to $45.4M on September 30, 2012.
  • The company expects that its current cash, cash equivalents and marketable securities will be sufficient to meet anticipated requirements for at least the next 24 months.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: